Paradigm shift in NMDA receptor drug development

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 3, 2005, Pages 427-429

  Lipton, Stuart A ^a,b   Chen, H S Vincent ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antagonist; Memantine; NMDA receptor

Indexed keywords

ADAMANTANE DERIVATIVE; CALCIUM CHANNEL; CALCIUM ION; CHOLINESTERASE INHIBITOR; DIZOCILPINE; GLUTAMIC ACID; GLYCINE; KETAMINE; MAGNESIUM ION; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PHENCYCLIDINE; SODIUM ION;

ALZHEIMER DISEASE; CALCIUM TRANSPORT; COMA; DEMENTIA; DEPRESSION; DROWSINESS; DRUG APPROVAL; DRUG BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HALLUCINATION; HUMAN; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTRANSMISSION; SODIUM TRANSPORT; UNITED STATES;

DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 21244458852     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.3.427     Document Type: Editorial

References (6)

1. CHEN H-S V, PELLEGRINI JW, AGGARWAL SK et al.; Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. (1992) 12:4427-4436.
2. LIPTON SA: Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. (1993) 16:527-532.
3. LIPTON SA, ROSENBERG PA: Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. (1994) 330:613-622.
4. CHEN H-S V, LIPTON SA: Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. (Lond.) (1997) 499:27-46.
5. CHEN H-S V, WANG YF, RAYUDU PV et al.: Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience (1998) 86:1121-1132.
6. REISBERG B, DOODY R, STÖFFLER A SCHMITT F, FERRIS S, MÖBIUS J: Memantine in Moderate-to-Severe Alzheimer's disease. N. Engl. J. Med. (2003) 348:1333-1341.